Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Consolidated net (loss) income	$ 2,091	$ 5,730
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	4,877	3,914
Impairment charges	24,311	0
Amortization of debt discount and debt issuance costs	902	936
Provision for allowances	2,254	642
Loss on early extinguishment of debt	1,568	0
Deferred income tax (benefit) expense	(6,288)	1,412
Gain on derivative liability	(12,865)	(2,509)
Acquisition-related contingent consideration	470	0
Equity compensation	1,767	1,216
Other non-cash costs	5	19
Changes in operating assets and liabilities:
Accounts receivable	9	(8,134)
Prepaid expenses and other assets	565	1,458
Income taxes	(665)	(329)
Accounts payable and accrued expenses	(5,007)	1,190
Other liabilities	(1,127)	452
Net cash provided by operating activities	12,867	5,997
Cash flows from investing activities
Acquisition-related settlements - Medical Staffing Network	(2,155)	0
Acquisition-related settlements - Mediscan	297	0
Purchases of property and equipment	(2,616)	(1,033)
Net cash used in investing activities	(4,474)	(1,033)
Cash flows from financing activities
Proceeds from borrowing on Senior Credit Facility	40,000	0
Debt issuance costs	(990)	0
Principal payments on Second Lien Term Loan	(30,000)	0
Extinguishment fees	(641)	0
Repayments on Senior Secured Asset-Based revolving credit facility	(65,200)	(34,800)
Borrowings under Senior Secured Asset-Based revolving credit facility	57,200	34,300
Repayments of capital lease obligations	(47)	(53)
Cash paid for shares withheld for taxes	(565)	(465)
Payment of contingent consideration	(17)	0
Cash payment to noncontrolling shareholder	(332)	(247)
Net cash used in financing activities	(592)	(1,265)
Effect of exchange rate changes on cash	(25)	(15)
Change in cash and cash equivalents	7,776	3,684
Cash and cash equivalents at beginning of period	2,453	4,995
Cash and cash equivalents at end of period	$ 10,229	$ 8,679